XML 17 R33.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenue (Tables) | 3 Months Ended
--- | ---
Jan. 31, 2020
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended January 31,
| 2020 |  | 2019
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total |  | Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions) |  |  |  |  |  |  |  |
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 209 |  |  | $ | 118 |  |  | $ | 167 |  |  | $ | 494 |  |  | $ | 168 |  |  | $ | 109 |  |  | $ | 156 |  |  | $ | 433 |
Europe | 167 |  |  | 92 |  |  | 133 |  |  | 392 |  |  | 164 |  |  | 91 |  |  | 128 |  |  | 383 |
Asia Pacific | 262 |  |  | 39 |  |  | 170 |  |  | 471 |  |  | 275 |  |  | 35 |  |  | 158 |  |  | 468 |
Total | $ | 638 |  |  | $ | 249 |  |  | $ | 470 |  |  | $ | 1,357 |  |  | $ | 607 |  |  | $ | 235 |  |  | $ | 442 |  |  | $ | 1,284 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended
| January 31,
| 2020 |  | 2019
| (in millions)
Revenue by End Markets |  |  |
Pharmaceutical and Biopharmaceutical | $ | 423 |  |  | $ | 391 |
Chemical and Energy | 312 |  |  | 308 |
Diagnostics and Clinical | 194 |  |  | 187 |
Food | 130 |  |  | 129 |
Academia and Government | 141 |  |  | 116 |
Environmental and Forensics | 157 |  |  | 153 |
Total | $ | 1,357 |  |  | $ | 1,284 |
Revenue by Type |  |  |
Instrumentation | $ | 593 |  |  | $ | 567 |
Non-instrumentation and other | 764 |  |  | 717 |
Total | $ | 1,357 |  |  | $ | 1,284 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2020:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2019 |  | $ | 386 |
Net revenue deferred in the period |  | 180 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (142 | )
Change in deferrals from customer cash advances, net of revenue recognized |  | 9 |
Currency translation and other adjustments |  | (1 | )
Ending balance as of January 31, 2020 |  | $ | 432 |

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration